Mesa Labs upgraded to Outperform from In Line at Evercore ISI

Evercore ISI upgraded Mesa Labs to Outperform from In Line with a price target of $125, up from $100. While the Life Science & Diagnostic Tools group has run up on potential biopharma turnaround, Mesa shares have lagged, notes the analyst. With biopharma consumables growing quarter-over-quarter, the firm thinks Mesa Labs “is a catch up trade,” the analyst tells investors.